Bank of Montreal’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-6,660
Closed -$22K 4993
2018
Q3
$22K Sell
6,660
-19,211
-74% -$69.3K ﹤0.01% 3685
2018
Q2
$98K Sell
25,871
-95,229
-79% -$464K ﹤0.01% 3133
2018
Q1
$495K Buy
121,100
+90,000
+289% +$419K ﹤0.01% 2231
2017
Q4
$144K Sell
31,100
-4,282
-12% -$23.6K ﹤0.01% 2836
2017
Q3
$251K Sell
35,382
-35,085
-50% -$252K ﹤0.01% 2570
2017
Q2
$509K Hold
70,467
﹤0.01% 2262
2017
Q1
$434K Buy
+70,467
New +$386K ﹤0.01% 2150
2016
Q2
Sell
-2,703
Closed -$13K 4456
2016
Q1
$13K Sell
2,703
-319
-11% -$1.27K ﹤0.01% 3542
2015
Q4
$16K Sell
3,022
-9,736
-76% -$46.3K ﹤0.01% 3477
2015
Q3
$45K Buy
12,758
+12,558
+6,279% +$84.1K ﹤0.01% 2966
2015
Q2
$2K Hold
200
﹤0.01% 3793
2015
Q1
$3K Hold
200
﹤0.01% 3740
2014
Q4
$3K Hold
200
﹤0.01% 3799
2014
Q3
$3K Sell
200
-2,230
-92% -$34.1K ﹤0.01% 3878
2014
Q2
$37K Buy
2,430
+2,230
+1,115% +$31.6K ﹤0.01% 3339
2014
Q1
$3K Hold
200
﹤0.01% 3880
2013
Q4
$3K Hold
200
﹤0.01% 3611
2013
Q3
$2K Sell
200
-50
-20% -$445 ﹤0.01% 3692
2013
Q2
$2K Buy
+250
New +$1.95K ﹤0.01% 3564

Bank of Montreal's KERX Position: Q4 2018 in Review

Bank of Montreal sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 6,660 shares — an estimated $22K sold.

Bank of Montreal first reported a position in KERX in Q2 2013 and held it in 19 quarters. The position peaked at $509K in Q2 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

  • Bank of Montreal reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • Bank of Montreal sold 6,660 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $22K.
  • Bank of Montreal first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 19 quarters.
  • Bank of Montreal's Keryx Biopharmaceuticals Inc position peaked at $509K in Q2 2017.
  • 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on Bank of Montreal's 13F filing for Q4 2018, filed 22 Jan 2019.